研究单位：[1]Wuhan YZY Biopharma Co., Ltd.[2]The 307th Hospital of Chinese People's Liberation Army[3]Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology
研究目的：
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
